利妥昔单抗治疗类风湿关节炎的长期持续性:UCL队列1998至2020年评估
该研究回顾性分析了1998至2020年间UCL专属门诊随访的404例接受利妥昔单抗治疗的RA患者,评估药物长期持续性和停药相关因素。中位随访55个月、中位治疗5个周期,31.2%患者停药,原发无效是主要原因;血清阴性及既往bDMARD失败者药物生存率更低,停药与既往bDMARD数量更多相关。
要点
- 多数RA患者经重复利妥昔单抗周期可实现良好疾病控制。
- 血清阴性及既往至少一种bDMARD失败者利妥昔单抗药物生存率更低。
- 停药与既往bDMARD数量更多相关,原发无效是主要停药原因。
核心结论
- 许多RA患者通过重复利妥昔单抗周期实现良好疾病控制,但血清阴性及既往bDMARD失败者停药风险更高。
研究设计与样本
- 回顾性研究,纳入1998至2020年UCL专属门诊随访的所有接受利妥昔单抗治疗的RA患者共404例。
- 采用Kaplan-Meier生存曲线、log-rank检验和Cox回归分析药物生存及停药相关因素。
主要发现
- 首次利妥昔单抗周期时中位病程10年、中位年龄57岁,中位总随访55个月、中位周期数5。
- 93.1%患者血清阳性,31.2%患者停用利妥昔单抗,原发无效占停药原因的42.1%。
- Kaplan-Meier曲线显示血清阴性患者及既往至少一种bDMARD失败者利妥昔单抗药物生存率更低。
- Cox回归分析显示利妥昔单抗停药与既往bDMARD数量更多相关。
临床怎么用
- 对血清阴性或既往多种bDMARD失败的RA患者,预期利妥昔单抗持续治疗可能性较低,需提前规划替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: B cell depletion therapy based on rituximab in patients with RA was pioneered at University College London Hospitals/University College London in 1998. The objective of this study was to evaluate long-term persistence of rituximab and identify factors associated with discontinuation of treatment. METHODS: Retrospective review of medical records from all rituximab-treated RA patients followed up in a dedicated clinic (1998-2020). Data collected included gender, disease duration, previous DMARDs, autoantibody status, age and concomitant therapy at first cycle, length of follow-up, and number of cycles. Drug survival and factors associated with drug discontinuation were analysed using Kaplan-Meier survival curves, log-rank test and Cox regression analysis. RESULTS: A total of 404 patients were included. Median disease duration and age at time of first rituximab cycle were 10 and 57 years, respectively. Median total follow-up was 55 months and median number of cycles five. 93.1% of patients were seropositive. Overall, 31.2% of patients stopped rituximab, with the largest reason for discontinuing being primary inefficacy (42.1%). Comparison of Kaplan-Meier curves showed that rituximab drug survival was lower in seronegative patients and in patients who had previously failed at least one biologic DMARD (bDMARD). Cox regression analysis revealed that rituximab discontinuation was associated with a greater number of previous bDMARDs. CONCLUSION: Many patients with RA achieve good control of their disease with repeated cycles of rituximab treatment. The most common reasons for treatment discontinuation were either primary or secondary inefficacy. Patients who were seronegative and who had previously failed other bDMARDs were more at risk of drug discontinuation.
引用
- Norris-Grey C, Cambridge G, Moore S, et al. Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020. Rheumatology (Oxford). 2022. PMID: 33769451. doi:10.1093/rheumatology/keab248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。